DOWN SYNDROME

 

DOWN SYNDROME

 

DEFINITION:

A chromosomal disorder resulting in a syndrome characterized by specific dysmorphic features (facies) and organ malformations.

EPIDEMIOLOGY:

  • incidence: 1/800 live births
    • 75% of fetuses with Trisomy 21 abort spontaneously
    • most common autosomal chromosomal disorder causing mental retardation
  • age of onset:
    • newborn
  • risk factors:
    • increased maternal age (although 80% are born to mothers <35 years)

HISTORY:

  • 1865 - John Langdon Down
    • first detailed description
  • 1930 - Brewster and Cannon
    • first to report an association between Down's & acute leukemia
  • 1954 - Schunk and Lehman
    • first to report an association between Down's & transient leukemia
  • 1959 - Lejeune
    • first to associate Down's with Trisomy 21

GENETICS/PATHOGENESIS:

1. Genetics

1. Trisomy 21 (95%)

  • due to non-disjunction during meiosis
    • 80-90% due to maternal non-disjunction
    • 10-20% " paternal "
  • 1% recurrence risk

2. Unbalanced Translocation (3-4%)

  • 50% are sporadic (de novo)
  • 50% are due to a balanced translocation in one parent
  • recurrence risk:
    • 100% in parent with a 21:21 translocation
    • 16% in mother with a 21:acrocentric chrom. transloca.
    • 5% in father "

3. Mosaicism (1-2%)

  • due to nondisjunction after meiosis
  • ? recurrence risk

2. Pathogenesis

  • trisomy of only the bottom 1/3 of chromosome 21 is sufficient to account for Down's phenotype
  • chrom. 21: the 800 genes in the 21q22 band appear to be those responsible for the pathogenesis
  • trisomy results in a 50% increased "dose" of certain proteins:
  • 1. SOD-1
    • superoxide dismutase
    • protects cells from oxygen-containing free radicals
    • ? role in MR and accelerated rate of aging
  • 2. Gart
    • phosphoribosylglycinamide synthetase
    • involved in purine synthesis
    • ? elevated purines -> mental retardation
  • 3. Ets-2
    • an oncogene
    • ? role in acute myelogenous leukemia M2
  • 4. Amyloid Beta Protein
    • major component of neurofibrillary plaques
    • ? pathogenesis in Alzheimers
  • 5. Alpha-A-crystallin Protein
    • structural component of lens of eye
    • ? role in formation of cataracts, Brushfield spots

3. Pathogenesis (of Transient Leukemia)

  • proposed mechanisms:
  • 1. spontaneously remitting leukemic clone
  • 2. stress (infections, CHD, etc.) -> over reaction of myeloid elements
  • 3. delay in WBC differentiation which resolves spontaneously as maturation progresses post-natally
  • 4. ineffective regulation of myeloporesis due to delayed maturation of the myeloid and other bone marrow elements

CLINICAL FEATURES:

1. Principle Clinical Features in the Newborn (Clin Peds 5:4 (1966))

  • 100% contain at least 4 of these
  • 89% contain at least 6 of these:
    • flat facial profile (90%)
    • poor Moro reflex (85%)
    • infantile hypotonia (80%)
    • hyperflexibility of joints (80%)
    • excess skin on neck (80%)
    • slanted palpebral fissures (80%)
    • dysplasia of pelvis (70%)
    • anomalous auricles (60%)
    • dysplastic 5th midphalanx (60%)
    • 45 simian crease (45%)

2. Diagnostic Index (J. Peds. 100(6): 903 (1982))

1. Dermatoglyphic Traits

  • hallucal pattern
  • forefinger pattern
  • palmar triradius

2. Physical Traits

  • ear length
  • internipple distance ratio

3. Clinical Findings

  • wide-spaced first toe
  • excess skin on back of neck
  • brushfield spots

3. Neurologic Manifestations

1. Hypotonia (100%)

  • at birth, in infancy, and as a toddler
  • may delay motor milestones but improves with age

2. Seizures (5-10%)

  • generalized, myoclonic most common type

3. Learning Disabled

  • borderline to moderate IQ range (from 80 -> 40)
  • processing problems:
    • better at visual than auditory processing
    • better at simultaneous than sequential processing

4. Global Developmental Delays

  • gross motor due to hypotonia
  • fine motor "
  • speech and language delay
    • 75% have an expressive language disability
  • behavioural problems
    • aggression, depression, inappropriate

5. Alzheimers

  • may affect 15-20% of adults with Down's
  • mean age of onset is 51 years (range 46-57 years)

4. Respiratory Manifestations

  • increased incidence of pulmonary hypoplasia and elevated pulmonary vascular resistence (+/- congenital heart defects) may lead to an increased risk of:
    • respiratory tract infections
    • acute and chronic airway obstruction
    • sleep apnea (small airways, large tonsils/adenoid, obesity)
    • cor pulmonale

5. Cardiovascular Manifestations (40%)

1. Structural Anomalies

1. Endocardial Cushion Defects

  • complete AV canal (49%)
  • VSD (22%)
  • ASD(secundum)- 14%
  • ASD(primum) - 8%

2. Others

  • 3 PDA (3%)
  • ToF (3%)
  • AV valve malformation (prolapse)
  • aberrant subclavian artery

2. Complications

  • elevated pulmonary blood flow -> irreversible pulmonary hypertension -> cor pulmonale
  • structural anomalies and complications are usually detected in the newborn period or in the first 6 weeks of life

6. Gastrointestinal Manifestations (12%)

1. Structural anomalies

  • duodenal atresia most common problem (+/- polyhydramnios, double bubble)
  • others: TEF, annular pancreas, Meckel's diverticulum, Hirschsprung's disease, imperforate anus

2. Complications

  • vomiting (bilious), constipation, failure to thrive, feeding difficulties and intolerance
  • structural anomalies and complications are usually detected in the newborn period or in the first 6 weeks

7. Genitourinary Manifestations

1. Structural Anomalies

  • 1. Kidney Malformation
    • uteropelvic junction (UPJ) obstruction with hydro-nephrosis
    • alterations in structure or maturation of parenchymal structures
  • 2. External Genitalia Malformation
    • 25-50% of males have hypospadias
    • 5% of males have undescended testes
    • small penis and scrotum
  • 8. Hematologic Manifestations

    1. Leukemia

    • risk is 10-30x that of general population
    • in newborns AML > ALL (2-4:1)
    • in children ALL > AML (2:1)

    2. Transient (Congenital) Leukemia

    • presence of a large number of blasts (megakaryoblasts) in the peripheral blood
    • may be variable leukocytosis +/- thrombocytopenia +/- anemia
    • clinically may be associated with lymphadenopathy and/or hepatomegaly/hepatosplenomegaly
    • 100% spontaneous remission rate within 1st weeks of life
    • occurs exclusively in Down's (82% in newborn period)
    • some cases may give rise to acute megakaryoblastic leukemia (AMKL) or other forms of leukemia during the first 3 years
    • - diagnosis is retrospective

    3. Autoimmune Disorders

    • higher than average likelihood of developing:
      • thyroiditis
      • alopecia areata (in 10-15%)
      • diabetes mellitus
      • rheumatoid-type arthropathy
      • autoimmune hemolytic anemia

    9. Endocrine Manifestations

    1. Thyroid Dysfunction (15%)

  • 1. Hypothyroidism
    • often due to lymphocytic thyroiditis
    • most present after the 1st decade
    • may appear in conjunction with diabetes mellitus, pre-cocious sexual maturation or hypoparathyroidism - may have congenital hypothyroidism
    • hyperthryoidism & euthyroid thyroiditis can also occur
  • 2. Growth Disorders

  • 1. Short Stature
    • both M & F at or near the 3rd % of general population
    • diminished growth velocity can occur at a variety of times (i.e., decreased adolescent growth spurt)
    • there are specific growth charts for Trisomy 21
  • 2. Obesity
    • especially at 2-3 years, 12-13 years, and in adult life
      • a common problem
  • 3. Sexual Maturation and Development

  • 1. Males
    • normal but fertility very rare
    • 25-50% have undescended testes
    • 5% have hypospadias
    • testes may be histologically abnormal
  • 2. Females
    • normal sexual maturation and development
    • menstruation
      • normal age of onset (no delay in onset of puberty)
      • normal menses
    • fertility
      • definite ovulation in 40%, probable in 15%, possible in 15%
      • abnormal follicular development is common
      • pregnancy is possible with a 50% chance of Trisomy
      • 21 occurring in the infant
  • 10. Dermatologic Manifestations

    1. Dry Skin (90%)

    • with secondary itching, eczema, and infections (i.e., recur-rent follicular skin infections)

    2. Syringomas

    • benign sweat gland tumors
    • F > M; onset at beginning of puberty
    • yellow or skin-coloured, soft 2-3 mm raised papules occur-ring singly or in groups
    • most commonly found around eyes but also on neck and thor-acic, axillary, umbilical, and pubic areas

    3. Others

    • alopecia areata (in 10%)
    • rapid aging of skin
    • increased risk of sunburn

    11. Musculoskeletal Manifestations

    1. Cervical Spine Problems

  • 1. Atlantoaxial Instability (14%)
    • incidence: 1/3000
  • 2. Spinal Cord Compression (1-2%)
    • with persistent neck pain, loss of bladder or bowel control, changes in sensation, long tract signs
  • 2. Others

    • bony anomalies of the cervical spine
    • subluxation or dislocation of hips and/or knees
    • pronation of feet at ankles, pes pannus, short broad hands, short sternum, decreased acetabular and iliac angle (CDH, dysplastic hips), see "Clinical features in Newborn"
    • hypotonia & ligamentous laxity predisposes to these problems

    12. Ocular Manifestations

    1. Major

    • congenital nystagmus or alternating esotropia
    • congenital cataracts and glaucoma
    • 60% with strabismus
    • 50% with refractive errors

    2. Minor

    • epicanthal folds, oblique palpebral fissures
    • blepharitis, keratoconus, Brushfield spots

    13. Oral and Dental Manifestations

    • delays and alterations in the sequence of tooth eruption
    • 100% with malocclusions (mandibular overjet, post. cross bite)
    • 60% with relative macroglossia
    • 50% with missing teeth
    • 37-60% with fissuring tongue, enlargement of vallate papillae

    14. Otorhinolaryngologic Manifestations

    1. Recurrent Otitis Media

    • 75% with sensorineuronal conductive hearing loss due to an accumulation of fluid in the middle ear space

    2. Midface Hypoplasia

    • nasolacrimal duct obstruction (in 20%)
    • obstructive sleep apnea
    • sinusitis and purulent rhinitis

    INVESTIGATIONS:

    1. Prenatal Screening/Diagnosis

    • chorionic villus sampling at 9-12 weeks
    • amniocentesis at 16-18 weeks
    • indications for:
      • advanced maternal age (>35 years)
      • previous child with Trisomy 21
      • balanced translocation in parent
      • prenatal U/S findings suggestive of Trisomy 21
      • altered maternal serum markers
        • decreased alpha fetoprotein
        • " human chorionic gonadotropin
        • " unconjugated estriol (uE3)

    2. Imaging Studies

    1. Cardiac

    • 2D-Echo, chest x-ray, EKG

    2. Gastrointestinal

    • abdominal x-ray, barium swallow/enema

    3. Renal

    • renal ultrasound

    4. Skeletal X-Rays

    • bone age for short stature
    • C-spine - an atlanto-dens space >5 mm is suggestive of atlantoaxial instability
    • sinusitis

    3. Serum

    • compensated respiratory acidosis (due to COPD)
    • elevated urea, creatinine, uric acid, decreased creatinine and uric acid clearance
    • CBC with blasts
    • TSH, T3, T4, thyroid antibodies
    • ? GH stimulation tests

    4. Others

    • EEG (hypsarrhythmias)

    MANAGEMENT:

    1. Neurologic Manifestations

    1. Seizures

    • Neurology consult, EEG, anticonvulsant medications

    2. Learning Disabilities

    • teaching methods which emphasize visual over auditory information

    3. Developmental Delays

    • early intervention
    • gross/fine motor - physiotherapy
    • speech/language - total communication techniques (signing or computers), speech therapy, special education
    • behaviour - mental health assistance, family counsel

    2. Respiratory Manifestations

    1. Sleep Apnea

    • decrease weight, repositioning during sleep, nasal CPAP, remove tonsils and adenoids

    2. Cor Pulmonale

    • early surgical correction of congenital heart disease (CHD)

    3. COPD

    • bronchodilators/steroids

    3. CVS Manifestations

    • all Down's patients should have a Cardiology consult and an echo done within the first few weeks of life
    • surgical correction of CHD

    4. Gastrointestinal Manifestations

    • surgical correction of malformations
    • treat functional problems, i.e., constipation
    • feeding team for problems

    5. Genitourinary Manifestations

    • follow serum urea, creatinine, uric acid
    • follow uric acid and creatinine clearance rates
    • ? role of imaging studies for screening for anomalies
    • surgical correction of hypospadia, undescended testes

    6. Hematologic Manifestations

    1. Leukemia

    • state of the art therapy noting increased risk of infec-tion and sensitivity to anti-folate chemotherapy
    • lower remission rate and a higher mortality with ALL in
    • Down's than general population
    • similar remission rate and mortality with AML in Down's and general population

    2. Transient Leukemia

    • moniter blasts in peripheral blood
    • spontaneous remission but risk of leukemia (ie. AMKL)

    3. Autoimmune Disorders

    • screen for manifestations i.e., TSH, blood sugar
    • ? role of pneumococcal and influenzae vaccines

    7. Endocrine Manifestations

    1. Thyroid

    • screen for clinical s/s of hypothyroidism (dry hair/skin, lethargy, cold intolerance, constipation, hoarse voice)
    • screen TFT (TSH, T3, T4) annually +/- thyroid antibodies

    2. Growth

    • moniter growth on charts for Down's
    • true GH deficiency is rare but may respond to GH supplements
    • obesity - caloric restriction, increase activity/exercise

    3. Reproduction

    • birth control and reproductive health issues need to be addressed (i.e., sterilization)

    8. Dermatology Manifestations

    • moisturizers, hypoallergenic creams for dry skin
    • steroid creams for eczema
    • topical or systemic antibiotics for infection
    • preventive measures to avoid sunburn
    • topical steroids, minoxidil for alopecia areata

    9. Musculoskeletal Manifestations

    1. C-Spine

    • see the Canadian Down's Society Guidlines
    • initially assessed at 2-4 years and repeated between 8-10 years
    • earlier assessment if indicated - neurologic findings:
      • loss of motor skills
      • asymmetric hypertonicity in lower limbs
      • increased clumsiness or tripping
      • widely-spaced stiff-legged gait
      • any upper motor neuron signs
      • loss of fine motor skills
      • torticollis, neck pain, headaches
    • if abnormal then must restrict activities - tumbling, div-ing, butterfly, collision sports

    2. Spinal Cord Compression

    • may require surgical stabilization (skeletal fixation) of cervical spine
    • ortho, neuro, neurosurg consults

    10. Ocular Manifestations

    • initial screen should occur in early infancy with follow-up at
    • 18 months and 5 and 15 years

    11. Oral and Dental Manifestations

    • routine preventive dental care
    • relative macroglossia may be corrected by oral or plastic sur-gery if indicated

    12. Otorhinolaryngologic Manifestations

    • audiologic evaluation by sound field testing or auditory brain-stem responses (ABR) should begin at 6 months and be repeated q6-12m during the preschool years
    • antibiotics for recurrent OM, sinusitis, or purulent rhinitis
    • myringotomy tubes for recurrent otitis media (OM)

    13. Genetics

    • genetic counselling if plans for another child
    • 80% survive to age 30 or beyond

    INTERNET LINKS:

    Down Syndrome WWW Page
    Down Syndrome Research Foundation and Resource Centre Home Page
    The National Down Syndrome Society
    National Association for Down Syndrome
    DS Growth Charts

     

     

    Pediatric Database - DOWN SYNDROME

    Pediatric Organization - Pedbase [at] Gmail.com